| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A sensory-motor hand prosthesis with integrated thermal feedback
|
Muheim, Jonathan
|
|
|
5 |
2 |
p. 118-125.e5
|
artikel
|
| 2 |
Balancing macrophage polarization via stem cell-derived apoptotic bodies for diabetic wound healing
|
Mao, Jiayi
|
|
|
5 |
2 |
p. 148-168.e8
|
artikel
|
| 3 |
Enfortumab vedotin and pembrolizumab as new first-line standard for metastatic urothelial cancer
|
Zhu, Xiaolin
|
|
|
5 |
2 |
p. 106-108
|
artikel
|
| 4 |
Gemcitabine with cisplatin and nivolumab: Redefining standard of care for first-line metastatic urothelial carcinoma?
|
Mathew Thomas, Vinay
|
|
|
5 |
2 |
p. 109-111
|
artikel
|
| 5 |
HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition
|
Baumert, Lukas S.
|
|
|
5 |
2 |
p. 126-131.e1
|
artikel
|
| 6 |
Isoform-selective TGF-β3 inhibition for systemic sclerosis
|
Sun, Tianhe
|
|
|
5 |
2 |
p. 132-147.e7
|
artikel
|
| 7 |
LIBRETTO-431: Is it time to reconsider randomized phase 3 trials for uncommon oncogenic drivers in non-small-cell lung cancer?
|
Russo, Alessandro
|
|
|
5 |
2 |
p. 112-114
|
artikel
|
| 8 |
MARIPOSA-2: Is the treatment worse than the disease?
|
Lee, Alexandria T.M.
|
|
|
5 |
2 |
p. 115-117
|
artikel
|
| 9 |
Olgotrelvir, a dual inhibitor of SARS-CoV-2 Mpro and cathepsin L, as a standalone antiviral oral intervention candidate for COVID-19
|
Mao, Long
|
|
|
5 |
2 |
p. 169-171
|
artikel
|
| 10 |
Rare Disease Day: Amplifying voices, advocating hope
|
Cederroth, Helene
|
|
|
5 |
2 |
p. 103-105
|
artikel
|
Tijdschrift beschrijving